8-K: Bausch Health Completes $4.4 Billion Senior Secured Notes Offering and New Credit Facilities

Bausch Health Companies Inc. finalizes a $4.4 billion notes offering and establishes new credit facilities to refinance existing debt and for general corporate purposes.

Summary

• Bausch Health Companies Inc. has completed a private offering of $4.4 billion in senior secured notes due in 2032 through its subsidiary, 1261229 B.C. Ltd.
• The notes bear an interest rate of 10.000%, payable semi-annually on April 15 and October 15, starting October 15, 2025.
• The proceeds from the notes, along with funds from new term loan facilities, will be used to repay existing debt, redeem senior secured notes, and for general corporate purposes.
• The company has also entered into a new senior secured credit agreement, including a $3.0 billion term loan and a $500 million revolving credit facility.
• The term loan facility amortizes in equal quarterly installments of 1% annually, starting September 30, 2025, with the balance due at maturity.
• The notes are secured by a first priority lien on substantially all assets of the issuer and certain guarantors, including a pledge of the issuer's equity interest in Bausch + Lomb Corporation.
• The issuer has the option to redeem the notes starting April 15, 2028, at specified percentages of the principal amount, plus accrued interest.
• Upon a change of control, noteholders can require the issuer to repurchase the notes at 101% of the principal amount, plus accrued interest.
• The credit agreement includes covenants that limit the company's ability to incur debt, pay dividends, create liens, and engage in transactions with affiliates.

Sentiment

Score: 7

Explanation: The document is primarily factual and descriptive, outlining the terms of a financial transaction. The sentiment is neutral to slightly positive, reflecting the completion of a significant financing event.

Positives

• The offering and new credit facilities allow Bausch Health to refinance existing debt, potentially improving its financial structure.
• The use of proceeds for general corporate purposes provides flexibility for future investments and operations.

Negatives

• The notes carry a high interest rate of 10.000%, increasing the company's interest expense.
• The credit agreement includes restrictive covenants that may limit the company's operational flexibility.

Risks

• The company's ability to meet its debt obligations depends on its future financial performance, which is subject to economic and market conditions.
• The restrictive covenants in the credit agreement could limit the company's ability to pursue certain growth opportunities.
• A change of control could trigger a requirement to repurchase the notes, potentially straining the company's finances.

Future Outlook

The document outlines the terms and conditions of the notes and credit facilities, providing a framework for the company's future financial activities and obligations.

Industry Context

The announcement reflects a common strategy in the pharmaceutical industry to manage debt and optimize capital structure through refinancing and new credit facilities.

Related Party Transactions

• The issuer intends to loan the net proceeds from the offering of the Notes, together with funds borrowed under the Term Loan Facility to the Company pursuant to an intercompany loan.

Stakeholder Impact

• Shareholders: The refinancing may improve the company's financial stability and flexibility.
• Creditors: The new notes and credit facilities establish new terms for debt repayment and security.
• Employees: The refinancing may provide greater job security by improving the company's financial health.

Next Steps

• The issuer will use the proceeds from the offering of the notes, together with proceeds of the Term Loan Facility (i) to repay in full and terminate the Company's existing credit agreement, (ii) to redeem all of its 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 6.125% Senior Secured Notes due 2027, 5.750% Senior Secured Notes due 2027 and its indirect subsidiary's 9.000% Senior Secured Notes due 2028, (iii) to pay related fees, premiums and expenses and (iv) for general corporate purposes.

Key Dates

Keywords

Senior Secured Notes, Credit Facilities, Bausch Health, Debt Refinancing, Collateral, Covenants, Redemption, Change of Control, Financial Metrics, Intercreditor Agreement